Your browser doesn't support javascript.
Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from India.
Kumar, Akash; Baghmar, Saphalta; Mehta, Prashant; Tiwari, Priya; Kumar, Lalit; Bakhshi, Sameer; Agarwal, Amit; Gupta, Ishaan; Trikha, Anjan; Bhatnagar, Sushma; Gogia, Ajay; Malik, Prabhat Singh; Sahoo, Ranjit Kumar; Rastogi, Sameer; Pramanik, Raja; Batra, Atul; Pushpam, Deepam; Sharma, Chitresh K; Sharma, Vinod; Kataria, Babita; Goyal, Kapil; Samaga, Shreyas; Bothra, Sneha J; Sharma, Atul.
  • Kumar A; Department of Medical Oncology, National Cancer Institute, New Delhi, India.
  • Baghmar S; Department of Medical Oncology, BL Kapur Hospital, New Delhi, India.
  • Mehta P; Department of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Gurugram, Haryana, India.
  • Tiwari P; Department of Medical Oncology, Artemis Hospital, Gurugram, Haryana, India.
  • Kumar L; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Bakhshi S; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Agarwal A; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Gupta I; Department of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Gurugram, Haryana, India.
  • Trikha A; Department of Anaesthesiology, Pain Medicine & Critical Care, All India Institute of Medical Sciences, New Delhi, India.
  • Bhatnagar S; Department of Onco-Anaesthesia & Palliative Medicine, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Gogia A; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Malik PS; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Sahoo RK; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Rastogi S; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Pramanik R; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Batra A; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Pushpam D; Department of Onco-Anaesthesia & Palliative Medicine, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Sharma CK; Department of Surgical Oncology, National Cancer Institute, New Delhi, India.
  • Sharma V; Department of Medical Oncology, National Cancer Institute, New Delhi, India.
  • Kataria B; Department of Medical Oncology, National Cancer Institute, New Delhi, India.
  • Goyal K; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
  • Samaga S; Department of Biochemical Engineering & Biotechnology, Institute of Technology, New Delhi, India.
  • Bothra SJ; Department of Medical Oncology/Hematology/BMT, Asian Institute of Medical Sciences, Gurugram, Haryana, India.
  • Sharma A; Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, New Delhi, India.
Indian J Med Res ; 155(5&6): 546-553, 2022.
Article in English | MEDLINE | ID: covidwho-2110448
ABSTRACT
Background &

objectives:

High mortality has been observed in the cancer population affected with COVID-19 during this pandemic. We undertook this study to determine the characteristics and outcomes of cancer patients with COVID-19 and assessed the factors predicting outcome.

Methods:

Patients of all age groups with a proven history of malignancy and a recent diagnosis of SARS-CoV-2 infection based on nasal/nasopharyngeal reverse transcriptase (RT)-PCR tests were included. Demographic, clinical and laboratory variables were compared between survivors and non-survivors groups, with respect to observed mortality.

Results:

Between May 11 and August 10, 2020, 134 patients were included from the three centres and observed mortality was 17.1 per cent. The median age was 53 yr (interquartile range 39-61 yr) and thirty four patients (25%) were asymptomatic. Solid tumours accounted for 69.1 per cent and breast cancer was the most common tumour type (20%). One hundred and five patients (70.5%) had received chemotherapy within the past four weeks and 25 patients (19.3%) had neutropenia at presentation. On multivariate analysis, age [odds ratio (OR) 7.99 (95% confidence interval [CI] 1.18-54.00); P=0.033], haemoglobin [OR 6.28 (95% CI 1.07-37.04); P=0.042] neutrophil-lymphocyte ratio [OR 12.02 (95% CI 2.08-69.51); P=0.005] and baseline serum albumin [OR 18.52 (95% CI 2.80-122.27); P=0.002], were associated with higher mortality. Recent chemotherapy, haematological tumours type and baseline neutropenia did not affect the outcome. Interpretation &

conclusions:

Higher mortality in moderate and severe infections was associated with baseline organ dysfunction and elderly age. Significant proportion of patients were asymptomatic and might remain undetected.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms / Neutropenia Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Humans / Middle aged Country/Region as subject: Asia Language: English Journal: Indian J Med Res Year: 2022 Document Type: Article Affiliation country: Ijmr.ijmr_1703_21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms / Neutropenia Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Humans / Middle aged Country/Region as subject: Asia Language: English Journal: Indian J Med Res Year: 2022 Document Type: Article Affiliation country: Ijmr.ijmr_1703_21